Patents by Inventor Krista Goodman

Krista Goodman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPV4 antagonists
    Patent number: 8450484
    Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: May 28, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
  • TRPV4 ANTAGONISTS
    Publication number: 20110130400
    Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Application
    Filed: July 24, 2009
    Publication date: June 2, 2011
    Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
  • Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors
    Publication number: 20080234261
    Abstract: Novel inhibitors of Rho-kinases are disclosed.
    Type: Application
    Filed: October 6, 2004
    Publication date: September 25, 2008
    Inventors: Dennis Lee, Robert A. Stavenger, Krista A. Goodman, Mark A. Hilfiker, Haifeng Cui, Andrew Q. Viet, Joseph P. Marino
  • Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
    Publication number: 20070123561
    Abstract: Novel inhibitors of Rho-kinases are disclosed.
    Type: Application
    Filed: October 6, 2004
    Publication date: May 31, 2007
    Inventors: Dennis Lee, Robert Stavenger, Krista Goodman, Mark Hilfiker, Haifeng Cui, Joseph Marino
  • Imidazopyridine derivatives as kinase inhibitors
    Publication number: 20050197328
    Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Application
    Filed: March 21, 2003
    Publication date: September 8, 2005
    Inventors: Nicholas Bailey, Mark Bamford, Haifeng Cui, Stephen Garland, Krista Goodman, Mark Hilfiker, Dennis Lee, Terence Panchal, Robert Stavenger, David Wilson, Jason Witherington